BioCryst Pharmaceuticals Inc. announced that it has filed aninvestigational new drug (IND) application with the FDA for itsdrug, BCX-34, for treating cutaneous T cell lymphoma. BCX-34inhibits the enzyme purine nucleoside phosphorylase.Researchers at the Birmingham, Ala., company have shown inanimal studies that the drug selectively prevents T cellproliferation. BioCryst recently filed an IND on this samecompound for treating psoriasis.
(c) 1997 American Health Consultants. All rights reserved.